Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SELLAS Life Sciences GroupSLS +0.72%28 Price-to-Tangible-Book is 20.77 as of Sep. 08, 2026. GuruFocus rates SLS with a GF Score™ of 28/100. Among 1,127 Biotechnology companies, SELLAS Life Sciences Group ranks worse than 92.37% on this metric.
Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.
SELLAS Life Sciences Group Price-to-Tangible-Book Related Terms
SELLAS Life Sciences Group Price-to-Tangible-Book Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SELLAS Life Sciences Group Price-to-Tangible-Book Chart
SLS vs ATAI, VRDN, NRIX: Price-to-Tangible-Book Comparison
For the Biotechnology subindustry, SELLAS Life Sciences Group's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SELLAS Life Sciences Group Price-to-Tangible-Book vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SELLAS Life Sciences Group's Price-to-Tangible-Book distribution charts can be found below:
* The bar in red indicates where SELLAS Life Sciences Group's Price-to-Tangible-Book falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.
SELLAS Life Sciences Group (SLS) has a Price-to-Tangible-Book of 20.77 as of Sep. 08, 2026. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on SELLAS Life Sciences Group and its competitors. According to the industry distribution chart, SELLAS Life Sciences Group ranks #1041 out of 1127 companies in the Biotechnology industry, placing it in the top 92.4%.
Is SELLAS Life Sciences Group's Price-to-Tangible-Book too high?
SELLAS Life Sciences Group's current Price-to-Tangible-Book is 20.77. The Biotechnology industry median Price-to-Tangible-Book is 3.38. SELLAS Life Sciences Group's value of 20.77 is 514.5% above this industry median. Based on the distribution chart, SELLAS Life Sciences Group ranks #1041 out of 1127 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, SELLAS Life Sciences Group has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does SELLAS Life Sciences Group's Price-to-Tangible-Book compare to ATAI and VRDN?
According to the Biotechnology industry distribution chart, SELLAS Life Sciences Group ranks #1041 out of 1127 companies for Price-to-Tangible-Book. This places SELLAS Life Sciences Group in the lower half of its industry. The industry median Price-to-Tangible-Book is 3.38. SELLAS Life Sciences Group's value of 20.77 is 514.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Price-to-Tangible-Book for a Biotechnology company?
The median Price-to-Tangible-Book among Biotechnology companies is 3.38, based on 1,127 companies in the industry. Companies in the top quartile (top 25%) have a Price-to-Tangible-Book significantly above this median, while those in the bottom quartile fall well below. However, Price-to-Tangible-Book should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SELLAS Life Sciences Group's current Price-to-Tangible-Book of 20.77 is 514.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Price-to-Tangible-Book mean?
A high Price-to-Tangible-Book can signal that a stock is expensive relative to its fundamentals. Price-to-tangible-book ratio is the ratio of share price to a company's tangible book value per share. View historical data on SELLAS Life Sciences Group and its competitors. For the Biotechnology industry, the median Price-to-Tangible-Book is 3.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SELLAS Life Sciences Group's current Price-to-Tangible-Book is 20.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SELLAS Life Sciences Group stock overvalued right now?
SELLAS Life Sciences Group (SLS) has a current Price-to-Tangible-Book of 20.77. The current Price-to-Tangible-Book is 20.77 and 514.5% above the Biotechnology industry median of 3.38. SELLAS Life Sciences Group's overall GF Score™ is 28/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Price-to-Tangible-Book calculated?
Price-to-Tangible-Book is calculated from a company's financial statements. For SELLAS Life Sciences Group (SLS), the current Price-to-Tangible-Book is 20.77 as of Sep. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
28GF Score
Get the complete analysis for SLS
Price-to-Tangible-Book is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLS has been successfully added to your 
